1.  Afshar-Oromieh,A., Wolf,M., Haberkorn,U., Kachelriess,M., Gnirs,R., Kopka,K., Schlemmer, HP., Freitag, MT.: Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging 44 (10), 1636-1646, 2017.

2.  Afshar-Oromieh,A., Sattler, LP., Mier,W., Hadaschik,BA., Debus,J., Holland-Letz,T., Kopka,K., Haberkorn,U.: The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine 58 (5), 750-755, 2017.

3.  Afshar-Oromieh,A., Haberkorn,U., Zechmann,C., Armor,T., Mier,W., Spohn,F., Debus,N., Holland-Letz,T., Babich,J., Kratochwil,C.: Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. European Journal of Nuclear Medicine and Molecular Imaging 44 (6), 950-959, 2017.

4.  Afshar-Oromieh,A., Holland-Letz,T., Giesel,F.L., Kratochwil,C., Mier,W., Haufe,S., Debus,N., Eder,M., Eisenhut,M., Schäfer,M., Neels,O., Hohenfellner,M., Kopka,K., Kauczor,H.U., Debus,J., Haberkorn,U.: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging 44 (8), 1258-1268, 2017.

5.  Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schaefer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U: CORRECTION: Diagnostic performance of Ga-68-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients (vol 44, pg 1258, 2017). European Journal of Nuclear Medicine and Molecular Imaging 44 (10), 1781-1781, 2017.  

6.  Altmann,A., Sauter,M., Roesch,S., Mier,W., Warta,R., Debus,J., Dyckhoff,G., Herold-Mende,C., Haberkorn,U.: Identification of a Novel ITG alpha(v)beta(6)-Binding Peptide Using Protein Separation and Phage Display. Clinical Cancer Research 23 (15), 4170-4180, 2017.

7.  Anwar,H., Sachpekidis,C., Schwarzbach,M., Dimitrakopoulou-Strauss,A.: Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: Response to mammalian target of rapamycin inhibitor therapy. Hellenic Journal of Nuclear Medicine 20 (2), 169-171, 2017.

8.  Baranski,A.C., Schäfer,M., Bauder-Wüst,U., Wacker,A., Schmidt,J., Liolios,C., Mier,W., Haberkorn,U., Eisenhut,M., Kopka,K., Eder,M.: Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjugate Chemistry 28 (9), 2485-2492, 2017.

9.  Cardinale,J., Schäfer,M., Benešová,M., Bauder-Wüst,U., Leotta,K., Eder,M., Neels,O.C., Haberkorn,U., Giesel,F.L., Kopka,K.: Preclinical Evaluation of F-18-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. Journal of Nuclear Medicine 58 (3), 425-431, 2017.

10. Dimitrakopoulou-Strauss,A., Ronellenfitsch,U., Cheng,C., Pan,L., Sachpekidis,C., Hohenberger,P., Henzler,T.: Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clinical and Translation Imaging 5 (3), 183-197, 2017.

11.  Fendler,W.P., Eiber,M., Beheshti,M., Bomanji,J., Ceci,F., Cho,S., Giesel,F., Haberkorn,U., Hope,T.A., Kopka,K., Krause,B.J., Mottaghy,F.M., Schoeder,H., Sunderland,J., Wan,S., Wester,H.J., Fanti,S., Herrmann,K.: 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging 44 (6), 1014-1024, 2017.

12.  Flechsig,P., Frank,P., Kratochwil,C., Antoch,G., Rath,D., Moltz,J., Rieser,M., Warth,A., Kauczor,HU., Schwartz,LH., Haberkorn,U., Giesel,FL.: Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients. Molecular Imaging and Biology 19 (2), 315-322, 2017.

13.  Freitag, M.T., Fenchel, M., Bäumer, P., Heußer, T., Rank, C.M., Kachelrieß, M., Paech, D., Kopka, K., Bickelhaupt, S., Dimitrakopoulou-Strauss, A., Maier-Hein, K., Floca, R., Ladd, M.E., Schlemmer, H.P., Maier, F.: Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. European Radiology 96, 12-20, 2017.

14.  Freitag, M.F., Radtke, J.P., Afshar-Oromieh, A., Roethke, M.C., Hadaschik, B.A., Gleave, M., Bonekamp, D., Kopka, K., Eder, M., Heusser, T., Kachelriess, M., Wieczorek, K., Sachpekidis, C., Flechsig, P., Giesel, F., Hohenfellner, M., Haberkorn, U., Schlemmer, H.P., Dimitrakopoulou-Strauss, A.: Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging 44 (5), 776-787, 2017.

15.  Gasch,C., Düwel,C., Kopka,K., Kratochwil,C., Vinsensia,M., Eiber,M., Maurer,T., Haberkorn,U., Hadaschik,B., Giesel,F.L.: Significance of PSMA imaging in prostate cancer. Urologe / A 56 (1), 3-12, 2017.

16.  Giammarile F, Muylle K, Delgado Bolton R, Kunikowska J, Haberkorn U, Oyen W: Dosimetry in clinical radionuclide therapy: the devil is in the detail. European Journal of Nuclear Medicine and Molecular Imaging 44 (12), 1-3, 2017.

17.  Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T, Kauczor HU, Schwartz LH, Haberkorn U, Flechsig P: Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging. Journal of Nuclear Medicine 58 (2), 282-287, 2017.

18.  Giesel,F.L., Hadaschik,B., Cardinale,J., Radtke,J., Vinsensia,M., Lehnert,W., Kesch,C., Tolstov,Y., Singer,S., Grabe,N., Duensing,S., Schäfer,M., Neels,O.C., Mier,W., Haberkorn,U., Kopka,K., Kratochwil,C.: F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 44 (4), 678-688, 2017.

19.  Giesel,F.L., Kesch,C., Yun,M., Cardinale,J., Haberkorn,U., Kopka,K., Kratochwil,C., Hadaschik,B.A.: 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clinical Genitourinary Cancer 15 (3), e497-e499, 2017.

20.  Haberkorn,U., Mier W, Kopka K, Herold-Mende C, Altmann A, Babich J: Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine 58 (Suppl 2), 27S-33S, 2017.

21.  Haberkorn,U., Giesel F, Morgenstern A, Kratochwil C: The Future of Radioligand Therapy: alpha, beta, or Both?. Journal of Nuclear Medicine 58 (7), 1017-1018, 2017.

22.  Haberkorn,U., Giesel,F., Kopka,K., Kratochwil,C.: Radiotherapy with PSMA ligands in prostate cancer. Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique 41 (3), 232-234, 2017.

23.  Hassel,JC., Jiang,H., Bender,C., Winkler,J., Sevko,A., Shevchenko,I., Halama,N., Dimitrakopoulou-Strauss,A., Haefeli,WE., Jaeger,D., Enk,A., Utikal,J., Umansky,V.: Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). OncoImmunology 6 (9), e1326440, 2017.

24.  Heusser,T., Mann,P., Rank,C.M., Schaefer,M., Dimitrakopoulou-Strauss,A., Schlemmer,H.P., Hadaschik,B.A., Kopka,K., Bachert,P., Kachelriess,M., Freitag,M.T.: Investigation of the halo-artifact in Ga-68-PSMA-11-PET/MRI. PLoS ONE 12 (8), e0183329, 2017.

25.  Hoffend,J., Sachpekidis,C., Dimitrakopoulou-Strauss,A.: [Response evaluation in nuclear medicine : Criteria, results and pitfalls]. Radiologe 57 (10), 834-839, 2017.

26.  Kasper,B., Gruenwald,V., Reichardt,P., Bauer,S., Rauch,G., Limprecht,R., Sommer,M., Dimitrakopoulou-Strauss,A., Pilz,L., Haller,F., Hohenberger,P.: Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer 76, 60-67, 2017.

27.  Kesch,C., Kratochwil,C., Mier,W., Kopka,K., Giesel,F.L.: Ga-68 or F-18 for Prostate Cancer Imaging. Journal of Nuclear Medicine 58 (5), 687-688, 2017.

28.  Kesch,C., Vinsensia,M., Radtke,J.P., Schlemmer,H.P., Heller,M., Ellert,E., Holland-Letz,T., Duensing,S., Grabe,N., Afshar-Oromieh,A., Wieczorek,K., Schäfer,M., Neels,O.C., Cardinale,J., Kratochwil,C., Hohenfellner,M., Kopka,K., Haberkorn,U., Hadaschik,B.A., Giesel,F.L.: Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. Journal of Nuclear Medicine 58 (11), 1805-1810, 2017.

29.  Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, Iagaru AH, Herfarth K, Haberkorn U, Debus J, Giesel FL: (68)Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. Journal of Nuclear Medicine 58 (12), 1943-1948, 2017.

30.  Kopka K, Benesova M, Barinka C, Haberkorn U, Babich J: Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. Journal of Nuclear Medicine 58 (Suppl 2), 17S-26S, 2017.

31.  Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A: Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. Journal of Nuclear Medicine 58 (10), 1624-1631, 2017.

32.  Loktev,A., Haberkorn,U., Mier,W.: Multicyclic Peptides as Scaffolds for the Development of Tumor Targeting Agents. Current Medicinal Chemistry 24 (20), 2141-2155, 2017.

33.  Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S: PARP inhibition in BRCA2-mutated prostate cancer. Annals of Oncology 28 (1), 189-191, 2017.

34.  Paech, D., Giesel, F.L., Unterhinninghofen, R., Schlemmer, H.P., Kuner, T., Doll, S.: Cadaver-specific CT Scans Visualized at the Dissection Table Combined with Virtual Dissection Tables Improve Learning Performance in General Gross Anatomy. European Radiology 27 (5), 2153-2160, 2017.

35.  Pan,L., Cheng,C., Haberkorn,U., Dimitrakopoulou-Strauss,A.: Machine learning-based kinetic modeling: a robust and reproducible solution for quantitative analysis of dynamic PET data. Physics in Medicine and Biology 62 (9), 3566-3581, 2017.

36.  Petersen LJ, Nielsen JB, Dettmann K, Fisker RV, Haberkorn U, Stenholt L, Zacho HD: 68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level

37.  Pushkarevskaya,A., Neuberger,U., Dimitrakopoulou-Strauss,A., Enk,A., Hassel,JC.: Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. Journal of Immunotherapy 40 (7), 282-285, 2017.

38.  Rahbar,K., Ahmadzadehfar,H., Kratochwil,C., Haberkorn,U., Schäfers,M., Essler,M., Baum,R.P., Kulkarani,H.R., Schmidt,M., Bartenstein,P., Pfestroff,A., Lützen,U., Marx,M., Prasad,V., Brenner,W., Heinzel,A., Ruf,J., Meyer,P.T., Heuschkel,M., Eveslage,M., Bögemann,M., Fendler,W.P., Krause,B.J.: German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. Journal of Nuclear Medicine 58 (1), 85-90, 2017.

39.  Sachpekidis, C., Hillengass, J., Goldschmidt, H., Anwar, H., Haberkorn, U., Dimitrakopoulou-Strauss, A.: Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. American Journal of Nuclear Medicine and Molecular Imaging 7 (4), 148-156, 2017.

40.  Sachpekidis,C., Hillengass,J., Goldschmidt,H., Wagner,B., Haberkorn, U., Kopka,K., Dimitrakopoulou-Strauss,A.: Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging 44 (1), 50-62, 2017.

41.  Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Asfhar-Oromieh A, Herrmann K, Eiber M: PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine 58 (10), 1545-1552, 2017.

42.  Stahl,V., Maier,F., Freitag,M.T., Floca,R.O., Berger,M.C., Umathum,R., Berriel Diaz,M., Herzig,S., Weber,M.A., Dimitrakopoulou-Strauss,A., Rink,K., Bachert,P., Ladd,M.E., Nagel,A.M.: In vivo assessment of cold stimulation effects on the fat fraction of brown adipose tissue using DIXON MRI. Journal of Magnetic Resonance Imaging 45 (2), 369-380, 2017.

43.  Vinsensia,M., Choyke,P.L., Hadaschik,B., Holland-Letz,T., Moltz,J., Kopka,K., Rauscher,I., Mier,W., Schwaiger,M., Haberkorn,U., Maurer,T., Kratochwil,C., Eiber,M., Giesel,F.: 68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer. Journal of Nuclear Medicine 58 (12), 1949-1955, 2017.

44.  Will,L., Sonni,I., Kopka,K., Kratochwil,C., Giesel,F.L., Haberkorn,U.: Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging 61 (2), 168-180, 2017.

45.  Winkler, J.K., Dimitrakopoulou-Strauss,A., Sachpekidis,C., Enk,A., Hassel,J.C.: Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients. Journal of the European Academy of Dermatology and Venereology 31 (9), e389-e391, 2017.

46.  Winkler,JK., Buder-Bakhaya,K., Dimitrakopoulou-Strauss,A., Enk,A., Hassel,JC.: [Malignant melanoma: Current status]. Radiologe 57 (10), 814-821, 2017.


nach oben
powered by webEdition CMS